Research News

Several DMD organizations recently teamed up to fund a Phase 2 clinical trial of a new therapy for Duchenne muscular dystrophy (DMD) – Carmeseal-MD. Carmeseal-MD…

Charley's Fund, Duchenne UK, and Joining Jack recently announced a collaborative grant to Dr. Dada Pisconti of the University of Liverpool in England. With this…

Harvard doctor and scientist Seward Rutkove recently published new data about Electrical Impedance Myography, a non-invasive outcome measure for Duchenne muscular dystrophy and other muscle diseases. Charley's…

It's taking a long time, but it's happening! Summit Therapeutics, a UK-based company we began supporting nine years ago, is making significant progress on its experimental…

While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…

You probably already know that Charley's Fund is supporting the development of several new medicines to slow or halt Duchenne's deadly progression. Our goal is…